RankAlpha logo
Back to Rankings

PBYI

Puma BiotechnologyB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings bull case is that NERLYNX demand was strong enough for management to raise 2026 revenue and net income guidance, while operating cash flow improved and debt was fully extinguished, leaving more room for alisertib development without an obvious near-term financing need [#8-K-2026-05-07].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Commercial concentration remains high because NERLYNX still drives nearly all product revenue, limiting room for execution misses.
Momentum
54
Value
70
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $9.00 · Bear $5.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum54 · Δ7d -6.6
Value70 · Δ7d +0.2
Sentiment48 · Δ7d +2.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
54
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
-25.7
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.4
Sentiment
48
33% active weight
Current posture
7d trendImproving
Δ7d
+2.4
Δ21d
+7.9
Why this grade

Composite grade B. Momentum 53.7 / Value 70.5 / Sentiment 47.6

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$362.4M
Beta
1.21
Shares Out
50.39M
P/E (TTM)
8.0
P/S (TTM)
1.41
P/FCF (TTM)
6.98
Rev YoY
-32.4%
EPS YoY
-58.0%
Gross Margin
+76.9%
Op Margin
+15.8%
Net Debt
-$33.92M
Current Ratio
1.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology